

Sustained Release Injectable Drugs

Technology, Therapeutics, Markets, &
Forecasts

Report Brochure

Greystone
Research Associates



Greystone Research Associates is pleased to announce the publication of a new market study. **Sustained Release Injectable Drugs: Technology, Therapeutics, Markets and Forecasts** is a comprehensive evaluation and analysis of the technology, products and participants providing the driving force behind this evolving segment of the healthcare sector.

The study is designed to provide drug company decision makers, drug delivery developers, device designers, healthcare marketers, and supply chain participants with a detailed understanding of the economics, technologies, disease segments, and commercial opportunities for injectable drug products engineered for controlled release. Provider organization business managers, healthcare administrators and investors will also benefit from this study.

Engineered Injectables that Address Chronic Conditions

Chronic conditions require drug administration over long periods of time, placing a greater emphasis on self-administration. With the shift away from caregiver interaction, drug safety and compliance/adherence become prominent concerns. These concerns, which are not new, are becoming magnified as the number of powerful new drugs reaching the market increases. For healthcare managers and public health officials, one way to address these issues is less frequent dosing. Using formulation technologies designed to modulate the effect of therapeutic substances, drug developers are creating formulations that exhibit extended-release profiles. These chemistries include polymers such as polyethylene glycol-complexed (PEGylated), which are used to product encapsulated and coated versions of new APIs. The goal is to address the requirement for patient-dependent, and therefore compliance-sensitive, drug treatment protocols such as multiple dosing through controlled release formulations that provide the desired therapeutic effect with dosing of once-a-day or less.




Table of Contents

Executive Summary	Infectious Disease
	Interferon
Injectable Drug Market	Hormone Deficiency
Dynamics	Estradiol
The Trend toward Self-	Somatropin
Administration	Testosterone
Injectable Drug Formulation	Metabolic Diseases
Technology	Acromegaly
Innovation in Injectable	Lanreotide
Device Designs	Octreotide
Therapeutic Demand Drivers	Neurology
Market Factors	Aripiprazole
Competitive Landscape	Fluphenazine
Risk Factors	Haloperidol
Sustained Release - Branded	Paliperidone
Formulation Technologies	Olanzapine
Biodegradable Polymers	Risperidone
Branded SR Formulation	Oncology
Technologies	Leukemia
Physical Process Control	Vincristine
Methods	Lymphoma
Sustained Release Injectables	Cytarabine
– Development Factors	Prostate
Formulation Factors	Goserelin
Stability	Leuprolide
Lyophilization	Triptorelin
Packaging	Pain Management
Administration Factors	Bupivacaine
SR Injectables – Product	Reproductive Health
Analysis & Market Sector	MedtroxyprogesteroneSylatr
Forecasts	on/
Addiction	Fertility
Naltrexone	Endometriosis
Diabetes	Company Profiles
Exenatide	

What You Will Learn

- What are the marketed sustained release injectable drug products, what sustained release formulation technologies are used, and who markets them?
- What are the major factors driving sustained release injectable drug demand?
- What sustained release injectable drug candidates are in late-stage clinical development and what is their potential impact?
- How important are drug developer-formulation technologist relationships in the sustained release market segment, and what are the key alliances in the industry?
- What are the essential formulation factors, delivery device selection issues, related technology factors and market development issues for sustained release injectable drug products?
- In what therapeutic market segments do sustained release injectables compete? What is their market share today? What will it be in 2028? What is their expected growth rate?
- What are the significant economic, technology, and regulatory factors affecting the market for sustained release injectables?

Report Format and Availability

This report is available electronic format. A site license for a single physical location and a global license are also available. Custom licensing options to address specific company user requirements are available by calling client services at 603-440-5710, or by emailing clientservices@greystoneassociates.org.

Methodology

Research methodology is based on primary research in the form of in-depth interviews with key market participants, technology developers, distributors, industry experts, and market influencers, a list that includes regulatory officials, industry trade groups, and materials standards organizations.

Primary data is evaluated and normalized against secondary sources including trade journal articles, technical literature, industry publications, company data sheets and published information, and statistical data from government agencies and trade associations.

Forecasts and projections of market demand and future market activity are derived using standard modeling and statistical techniques.

About Greystone Associates

Greystone Associates is a medical technology consulting firm focused on the areas of medical market strategy, product commercialization, venture development, and market research. We assist medical and healthcare market participants in achieving their business objectives through the creation of detailed development strategies, product commercialization programs, and comprehensive market and technology research and analysis.

Our market research publications are designed, researched and written to provide timely and insightful information and data on focused market segments, with the aim of providing market participants with the essential knowledge to refine and execute their marketing plans and financial targets.

Ordering Information

Orders may be placed via postal mail, e-mail or fax. Orders not accompanied by a purchase order must contain a telephone number for verification, and clearly indicate the physical shipping address and billing address.

Payment

We accept the following forms of payment:

Company Check: Please make checks payable to 'Greystone Associates'

Credit Cards: We accept MasterCard, Visa and American Express

Wire Transfers: See 'Wire Transfers' below for more information

Orders Outside the U.S.

Orders must be prepaid via credit card, company check in US funds and drawn on a US bank, or wire transfer.

Email to
research@greystoneassociates.org

Wire Transfers: TD Banknorth
 300 Franklin Street
 Manchester, NH 03103
 (Call for Account Information)

Mailing Address: Greystone Research Associates
 Client Services
 P.O. Box 1362
 Amherst, NH 03031

Sustained Release Injectable Drugs

Technology, Therapeutics, Markets & Forecasts

Select	Format	License	Price (U.S. Funds)	Total
<input type="checkbox"/>	PDF	Single User License	\$3,850.00	
<input type="checkbox"/>	PDF	Site License	\$5,500.00	
<input type="checkbox"/>	PDF	Global License	\$7,500.00	
Total Payment (U.S. funds)				

Method of Payment: Company Check    Wire Transfer (International)

Card Number: _____ Name on Card _____

Expiration Date: _____ Card CVV _____ Signature _____

Billing Information	Shipping Information
Name:	<input type="checkbox"/> Click here if same as Billing Information Name:
Title:	Title:
Company:	Company:
Street Address:	Street Address:
City,State/Province:	City,State/Province:
Country/Postal Code:	Country/Postal Code:
Phone:	Phone:
Fax:	Fax:
Email:	Email: